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Summary 
A simple routine method is described for simultaneous assay of total urinary 
adrenaline, noradrenaline and dopamine. The catecholamines are pre-purified on a 
small ion-exchange column, separated by reversed phase ion-pair liquid chromatog- 
raphy, and are quantitated by electrochemical detection. The method was routinely 
applied to 422 urines. Elevated values were found in four urine specimens obtained 
from patients with histologically proven phaeochromocytomas. Virtually no inter- 
ference by endogenous or exogenous compounds was found. Values for urinary 
catecholamines determined by fluorimetric analysis agreed with those obtained by 
high pressure liquid chromatography with electrochemical detection. Within-day 
CVs for the compounds ranged from 5.2- 11.9%, between-day CVs from 3.3-6.6%. 
The normal range (95% confidence level) was 20-230 pg/24 h for noradrenaline and 
l-35 pg/24 h for adrenaline. 
Introduction 
The determination of urinary catecholamine excretion is useful in the diagnosis of 
phaeochromocytoma, neuroblastoma and in monitoring the treatment of these 
tumours. High pressure liquid chromatography (HPLC) has been proposed for the 
determination of adrenaline and noradrenaline after urinary extraction with Al,O, 
[ 11, or boric acid gel [2], or a combination of both [3]. For detection UV-absorbtion 
[l], fluorescence [4,5], and electrochemical [6,7] methods have been described. But 
these methods are not in common use, because they are either very tedious [3], or not 
sensitive enough [ 1,5]. 
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We describe a method for the assay of urinary catechol~nes using disposable 
columns pre-filled with a weak cation ion exchange resin for sample pre-purification. 
The catecholamines are eluted from the resin with boric acid and separated by 
HPLC. Detection is performed with an electrochemical detector. This analytical 
technique provides sensitivity, specificity and precision. The procedure has been 
applied to urine samples from hypertensive patients and appears to be free of 
interference by drugs, drug metabolites and endogenous compounds. 
Materials 
Noradrenaline, adrenaline and the kit for urinary catecholamine determination 
were obtained from Bio-Rad laboratories (Munich, FRG). Dihydroxybenzylamine 
(DHBA), ~-~-butyla~ne and dopamine were from Sigma Chemical Co. (St. Louis, 
MO, USA). Octylsulfonate (Pi&S) was purchased from Waters Associates (Milford, 
USA). All other chemicals were of analytical grade and were obtained from Merck 
(Darmstadt, FRG). 
Patients 
Patients were advised to discontinue all medication 2 days before urine collection. 
Patients followed no dietary restrictions except that no tea or coffee was allowed 
during urine collection. 
Methods 
Urine ~5ll~&~i5n 
Because of the paroxysmal nature of catecholamine secretion only 24-h urine was 
analysed. The specimen was collected in a plastic container with 20 ml 6 mol/l HCl 
as stabilizer. After collection the volume was determined and an aliquot was 
removed for analysis. The aliquot was stored up to 4 weeks at -20°C without the 
loss of catecholamine. 
Sample treatment 
5 ml urine were transferred to a 110 x 30 mm plastic tube. After adjusting the pH 
to 0.5-l with 6 mol/l HCl the urines were boiled in a water bath for 20 min. 
Thereafter the pH was adjusted to 6.5 with 0.5 mol/l NaOH using a Dosimate 535 
(Metrohm, Her&au, Switzerland), and the sample was poured into a column pre-filled 
with cation exchange resin (Na-form) with carboxylic acid exchange groups (Bio-Rad 
laboratories, Munich, FRG). After washing twice with 10 ml water, the catechola- 
mines were eluted with 8 ml boric acid, 40 g/l. 
For internal standardisation (not possible for fluorescence measurement) 0.5 ml 
10 mg/l DHBA was added to 5 ml urine before sample treatment. 
Preparation of urine standards 
Pooled urine from normal persons was adjusted to pH 10 with cont. NH, to 
destroy endogenous free catecholamines. After standing for 3 h at 25°C the urine 
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was acidified with 6 mol/l I-K1 to pH 2 and stored in 5-ml portions at -20°C. 
Before use, adrenaline, noradrenaline and dopamine, were added to a S-ml sample to 
yield final concentrations of 200, 200 and 500 pgg/l, respectively. Standards and 
blanks were analysed as described below and used for calculation of unknowns. 
Fluorescence analysis 
We determined total catecholamines in urine by the method of Sandhu and Freed 
[8] using the catecholamine kit from Bio-Rad according to the manufacturer’s 
instructions. Fluorescence was measured with a Farrand spectrophotofluorometer 
(Kontron, Eching, FRG) at 520 nm with excitation at 405 nm. Calculations were 
made by solving a simultaneous equation based on readings obtained from the 
standards. The concentration of dopamine was measured as described in [9]. 
Liquid chromatographic analysis 
The high pressure liquid chromatography (HPLC) system consisted of a solvent 
delivery system M 45, an automatic sample injector WISP 710 B and a 5 1 C,, 
column RCM 100 (id. 8 mm), all from Waters Associates (Milford, MA, USA). The 
electr~he~cal detector E 656,641 from Metrohm (Herisau, Switzerland) with a 
glassy carbon electrode was used. The detector potential was set at 0.8 V vs. an 
Ag/AgCl reference electrode. The isocratic solvent consisted of a mixture of 5 ~01s. 
of CH,OH and 95 ~01s. of buffer of the following composition; 0.1 mol/l sodium 
acetate, 20 mmol/l citric acid, 1 mmol/l dibutylamine, 0.1 mmol/l EDTA and 0.5 
mmol/l octanesulphonate. The buffer was filtered (0.45 pm Millipore filters) and 
degassed before use. The flow rate was set at 1.5 ml/mm and 25 ~1 of the boric acid 
eluate were injected. The peak height of unknown samples was compared with 
standards prepared as described above. When internal standard (DHBA) was used 
results were corrected for the loss during sample treatment. 
Statistical analysis was performed by the Wilcoxon-test. 
Results and discussion 
The chromatogram of the urine from a normal person is shown in Fig. 1. The lack 
of interfering peaks allows determination of the catecholamines close to detection 
limits. Retention time and detection limits are listed in Table I. The calibration 
curves were linear up to 1000 pg/l for each analyte. The mean (+ SD) recoveries 
(n = 10) were as follows: noradrenaline 79.6 f 2.9%, adrenaline 84.8 + 4.2%, and 
dopamine 93.3 + 6.2%. The means and the day-to-day CV’s calculated from a 
5-month period are shown in Table II together with the corresponding within-day 
CVs. In these studies, urinary catecholamines were determined with fluorescence and 
liquid chromato~ap~c analysis without internal standard (interferes with fluores- 
cence analysis). Urinary catecholamines of 24 normal persons were determined by 
HPLC and fluorescence analysis. The correlation of the two methods was y = 0.94~ 
+ 4.2 (r = 0.986) for noradrenaline, y = 0.54.x + 0.2 (r = 0.938) for adrenaline and 
y = 0.9 17x - 1.1 (r = 0.976) for dopamine. The two methods correlate fairly well, but 
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TABLE I 
DATA OF CATECHOLAMINE ANALYSIS BY HPLC 
Compound Retention 
time (min) 
Detection limit * 
absolute 
(pg) 
cont. 
(I.Lg/l) 
Noradrenaline 4.5 35 1.4 
Adrenaline 6.1 38 1.5 
Dopamine 12.1 70 2.8 
DHBA 7.8 _ _ 
* Calculated for 25 ~1 injection volume and for a detector sensitivity of 1 nA at full scale. 
Experimental conditions are described in the ‘Method’ section. 
b i tr li ;6 
minutes 
Fig. 1. Chromatogram of a urine sample from a normal person prepurified on a cation exchanger. 25 pl 
were injected and separated on a 5 p C,,-RCM 100 column. Electrochemical detection with electric 
potential set at +0.8 V. Solvent conditions and other details are described in the ‘Methods’ section. The 
catecholamine concentrations correspond to 20.7 pg/l noradrenaline (N); 3.7 cg/l adrenaline (A); 100 
gg/l DHBA, and 101 pg/l dopamine (D). 
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we found approximately half the adrenaline levels when determined by HPLC, 
which is in good agreement with [3]. 
Correlation of the fluorescence and HPLC data was not as good for catechola- 
mine determination in urines from hypertensive patients, although patients that had 
not stopped with their drugs were eliminated (Fig. 2, A and B). 
This suggests that minor amounts of drugs or drug metabolites may still have 
been present and interfered with the fluorescence analysis. Such an interference is 
described for cy-methyldopa in the literature [lo]. In our studies treatment with 
a-methyldopa (250 mg/day) resulted in two extra peaks, probably metabolites of 
cr-methyldopa which appeared after dopamine and did not interfere with the assay. 
We found that Fenistil@, an antihistaminic drug, and Trandate@ also interfere with 
fluorimetric but not HPLC analysis. This was shown with urines to which these 
drugs were added before sample treatment, and also with urine from patients 
undergoing therapy with these drugs. Accordingly, the following drugs were found 
not to interfere analytically with the described method: allopurinol, aspirin, caffeine, 
clonidine, dihydralazine, digoxin, indometacin, insulin, nitrofurantoin, prazosin, 
propanolol, quinidine, reserpine, thyroxine. We have now analysed 422 urine sam- 
ples from hypertensive patients, most of them not omitting drugs before urine 
collection, and no interference with the HPLC catecholamine determination could 
be seen. It appears that the combination of ion exchange chromatography, reversed- 
phase chromatography and electrochemical detection lowers errors due to drug 
interference. 
Data on catecholamine excretion of four patients with phaeochromocytoma are 
given in Table III. The diagnosis of phaeochromocytoma was confirmed by histo- 
logical examination of tissues removed at surgery. Noradrenaline excretion was 
greatly increased in all cases with fairly good agreement of the results obtained by 
either fluorescence- or HPLC determination. In contrast, adrenaline measurements 
TABLE II 
PRECISION OF THE CATECHOLAMINE ASSAY 
The determination of urinary catecholamines was performed by HPLC with amperometric detection as 
described in the ‘Method’ section. The within-run (A) and day-to-day (B) pm&ions are shown. 
” Noradrenaline Adrenaline Dopamine 
mean cv mean cv mean cv 
(PS/l) (‘k;) (KS/l) (W) (PS/l) (S) 
Level 1 A 20 28.8 8.0 * 131 2.6 
B 20 28.6 12.2 * 135 8.2 
Level 2 A 20 307 3.3 51.0 6.6 255 4.1 
B 21 301 6.5 49.4 11.9 248 5.2 
Level 3 A 20 135 3.3 10.6 13.8 393 1.9 
B 20 135 4.0 9.6 30.4 346 3.0 
* Value below detection limit. 
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Fig. 2. Correlation of the daily excreted amounts of urinary adrenaline (A) and noradrenaline (3) from 
hypertensive patients determined either by fluorescence analysis or by liquid c~omat~aphy (n = 37). 
Values marked with M, T and F are urines from patients receiving Methyidopa*, Trandate”, and 
FenistilaP, respectively. 
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TABLE III 
URINARY CATECHOLAMINE EXCRETION OF NORMAL PERSONS AND PATIENTS WITH 
PHAEOCHROMOCYTOMA 
The 95% confidence range for a collective of normal persons (n = 64) was 20-230 pg/24 h for 
noradrenaline and 1.0-35 pg/24 h for adrenaline. 
Patient 
No. 
Noradrenaline 
(/.tg/ 24b) 
fluorescence HPLC 
Adrenaline 
(pg/24 b) 
fluorescence HPLC 
I 720 966 57 456 
2 2251 2.569 49.9 18.9 
3 2450 2218 50.0 2 
4 2879 2 600 266 371 
Analytical details are described in the ‘Method’ section. 
yielded variable results with both methods. The reason for this discrepancy is not 
clear. Fourteen days after removal of the tumour, the urinary catecholamine levels 
were found to be normal. 
Age-dependent reference values for both, free and total adrenaline, noradrenaline, 
and dopamine are currently determined in our laboratory and will be published 
elsewhere. 
In conclusion, the described method offers an accurate, precise catecholamine 
assay free of drug interference which is associated with the fluorimetric assay. In 
addition, the electrochemical detection is highly specific and more sensitive than the 
fluorimetric detection that has been described [4,5]. The speed and reproducibility at 
sample pre-purification make this catechola~ne assay highly suitable for clinical 
use. 
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